{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T14:40:45Z","timestamp":1789656045171,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1A2C1092928"],"award-info":[{"award-number":["2022R1A2C1092928"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1A2C1092928"],"award-info":[{"award-number":["2022R1A2C1092928"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>External beam radiation therapy (RT) has shown promising effects for hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT) in recent studies. However, there is still a lack of consensus on the optimal RT scheme for PVTT treatment. We evaluated the efficacy and safety of image-guided 10-fraction hypofractionated RT in these patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Between January 2016 and March 2022, a total of 95 HCC patients with PVTT received 10-fraction hypofractionated image-guided radiation therapy (IGRT) at two institutes, and 69 patients were analyzed. Follow-up imaging was performed at three-month intervals after the completion of RT. The extent of PVTT was described according to the Liver Cancer Study Group of Japan classification: Vp1\u2009=\u2009segmental portal vein branch, Vp2\u2009=\u2009right\/left anterior\/posterior portal vein, Vp3\u2009=\u2009right\/left portal vein, and Vp4\u2009=\u2009main portal vein. Response evaluation was performed using Response Evaluation Criteria in Solid Tumors, version 1.1. Freedom from local progression (FFLP), progression-free survival (PFS), and overall survival (OS) were calculated from the start date of RT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The median prescribed dose of 50\u00a0Gy (range: 40-50\u00a0Gy; biologically effective dose [BED]: 56-75Gy<jats:sub>10<\/jats:sub>) was delivered in 10 fractions. In this cohort, 4.3% of patients had Vp1, 20.3% had Vp2, 37.7% had Vp3, and 37.7% had Vp4. Median Planning target volume was 105.3\u00a0cc (interquartile range [IQR], 74.1\u2013179.4\u00a0cc). Fifty-two (75.4%) patients received 50\u00a0Gy. With a median follow-up of 10.2\u00a0months (IQR, 6\u201321\u00a0months), the median OS was 20.3\u00a0months, and 1-year FFLP, PFS, and OS rates were 88.7%, 26.9%, and 62.2%, respectively. At 3\u00a0months follow-up, 13.0% had a complete response, 36.2% had a partial response, 46.4% had a stable disease and 4.4% had a progressive disease. In the multivariate analysis, alpha-fetoprotein level\u2009\u2265\u2009600\u00a0IU\/ml (hazard ratio [HR] 2.06, <jats:italic>p<\/jats:italic>\u2009=\u20090.03), Child\u2013Pugh Class B or C (HR 2.30, <jats:italic>p<\/jats:italic>\u2009=\u20090.02), and stage IVA or IVB (4.05, <jats:italic>p<\/jats:italic>\u2009=\u20090.02) were significantly related to OS. During the follow-up period, there were 2 (2.9%) cases of grade\u2009\u2265\u20093 toxicity: grade 3 liver enzyme elevation (<jats:italic>n<\/jats:italic>\u2009=\u20091), and acute cholangitis (<jats:italic>n<\/jats:italic>\u2009=\u20091).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Hypofractionated RT demonstrated promising local PVTT control and OS rates with acceptable toxicity. These data suggest that 10-fraction image-guided hypofractionated RT (BED: 56\u201375 Gy<jats:sub>10<\/jats:sub>) is a feasible treatment option for PVTT in HCC patients.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-13739-3","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:17:51Z","timestamp":1745194671000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of image-guided hypofractionated radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: a retrospective, multicenter study"],"prefix":"10.1186","volume":"25","author":[{"given":"Sang Min","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Hwa","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hwan","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Jun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Jong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Cheol","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eui Kyu","family":"Chie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Su","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"13739_CR1","unstructured":"Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3:524\u201348."},{"key":"13739_CR2","unstructured":"World Health Organization International Agency for Research on Cancer (IARC). Global Cancer Observatory: Cancer Today. Lyon, France: World Health Organization. https:\/\/gco.iarc.fr\/. Accessed 14 Mar 2023."},{"key":"13739_CR3","doi-asserted-by":"publisher","first-page":"e14070","DOI":"10.1097\/MD.0000000000014070","volume":"98","author":"C-Y Wang","year":"2019","unstructured":"Wang C-Y, Li S. Clinical characteristics and prognosis of 2887 patients with hepatocellular carcinoma: A single center 14 years experience from China. Medicine (Baltimore). 2019;98:e14070.","journal-title":"Medicine (Baltimore)"},{"key":"13739_CR4","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1186\/s12885-021-08904-3","volume":"21","author":"J Ding","year":"2021","unstructured":"Ding J, Wen Z. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. BMC Cancer. 2021;21:1157.","journal-title":"BMC Cancer"},{"key":"13739_CR5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"13739_CR6","doi-asserted-by":"publisher","first-page":"e13542","DOI":"10.1111\/eci.13542","volume":"51","author":"M Guarino","year":"2021","unstructured":"Guarino M, Cucchetti A, Pontillo G, Farinati F, Benevento F, Rapaccini GL, et al. Pattern of macrovascular invasion in hepatocellular carcinoma. Eur J Clin Invest. 2021;51:e13542.","journal-title":"Eur J Clin Invest"},{"key":"13739_CR7","doi-asserted-by":"crossref","unstructured":"Giannelli G, Pierri F, Trerotoli P, Marinosci F, Serio G, Schiraldi O, et al. Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival. A retrospective clinical study of 150 cases. Hepatol Res. 2002;24:50.","DOI":"10.1016\/S1386-6346(02)00027-X"},{"key":"13739_CR8","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1111\/liv.13988","volume":"39","author":"A M\u00e4hringer-Kunz","year":"2019","unstructured":"M\u00e4hringer-Kunz A, Steinle V, D\u00fcber C, Weinmann A, Koch S, Schmidtmann I, et al. Extent of portal vein tumour thrombosis in patients with hepatocellular carcinoma: The more, the worse? Liver Int. 2019;39:324\u201331.","journal-title":"Liver Int"},{"key":"13739_CR9","doi-asserted-by":"publisher","first-page":"537526","DOI":"10.3389\/fonc.2020.537526","volume":"10","author":"L-X Zhang","year":"2020","unstructured":"Zhang L-X, Luo P-Q, Chen L, Song D, Xu A-M, Xu P, et al. Model to predict overall survival in patients with hepatocellular carcinoma after curative hepatectomy. Front Oncol. 2020;10:537526.","journal-title":"Front Oncol"},{"key":"13739_CR10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76:681\u201393.","journal-title":"J Hepatol"},{"key":"13739_CR11","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"13739_CR12","doi-asserted-by":"crossref","unstructured":"Finn RS, Galle PR, Ducreux M, Cheng A-L, Reilly N, Nicholas A, et al. Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and\/or Contralateral Portal Vein Invasion in IMbrave150. Liver Cancer. 2024;13:655\u201368.","DOI":"10.1159\/000539897"},{"key":"13739_CR13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/ajco.13361","volume":"17","author":"HS Choi","year":"2021","unstructured":"Choi HS, Kang KM, Jeong BK, Jeong H, Lee YH, Ha IB, et al. Effectiveness of stereotactic body radiotherapy for portal vein tumor thrombosis in patients with hepatocellular carcinoma and underlying chronic liver disease. Asia-Pac J Clin Oncol. 2021;17:209\u201315.","journal-title":"Asia-Pac J Clin Oncol"},{"key":"13739_CR14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1001\/jamaoncol.2017.5847","volume":"4","author":"SM Yoon","year":"2018","unstructured":"Yoon SM, Ryoo B-Y, Lee SJ, Kim JH, Shin JH, An JH, et al. Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncol. 2018;4:661\u20139.","journal-title":"JAMA Oncol"},{"key":"13739_CR15","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/01.coc.0000239147.60196.11","volume":"29","author":"TH Kim","year":"2006","unstructured":"Kim TH, Kim DY, Park J-W, Kim YI, Kim SH, Park HS, et al. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol. 2006;29:568\u201375.","journal-title":"Am J Clin Oncol"},{"key":"13739_CR16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.radonc.2007.07.005","volume":"84","author":"R Toya","year":"2007","unstructured":"Toya R, Murakami R, Baba Y, Nishimura R, Morishita S, Ikeda O, et al. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiother Oncol. 2007;84:266\u201371.","journal-title":"Radiother Oncol"},{"key":"13739_CR17","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1111\/liv.13191","volume":"37","author":"JH Im","year":"2017","unstructured":"Im JH, Yoon SM, Park HC, Kim JH, Yu JI, Kim TH, et al. Radiotherapeutic strategies for hepatocellular carcinoma with portal vein tumour thrombosis in a hepatitis B endemic area. Liver Int. 2017;37:90\u2013100.","journal-title":"Liver Int"},{"key":"13739_CR18","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1200\/JCO.2012.44.1659","volume":"31","author":"A Bujold","year":"2013","unstructured":"Bujold A, Massey CA, Kim JJ, Brierley J, Cho C, Wong RKS, et al. Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013;31:1631\u20139.","journal-title":"J Clin Oncol"},{"key":"13739_CR19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.5603\/RPOR.a2021.0016","volume":"26","author":"R Kumar","year":"2021","unstructured":"Kumar R, Yadav HP, Thaper D, Kamal R, Gupta A, Kirti S. Efficacy and toxicity of SBRT in advanced hepatocellular carcinoma with portal vein tumor thrombosis - a retrospective study. Rep Pract Oncol Radiother. 2021;26:573\u201381.","journal-title":"Rep Pract Oncol Radiother"},{"key":"13739_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.radonc.2016.12.014","volume":"122","author":"DY Kim","year":"2017","unstructured":"Kim DY, Park J-W, Kim TH, Kim BH, Moon SH, Kim SS, et al. Risk-adapted simultaneous integrated boost-proton beam therapy (SIB-PBT) for advanced hepatocellular carcinoma with tumour vascular thrombosis. Radiother Oncol. 2017;122:122\u20139.","journal-title":"Radiother Oncol"},{"key":"13739_CR21","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.3390\/cancers16112050","volume":"16","author":"T Ishida","year":"2024","unstructured":"Ishida T, Mizumoto M, Saito T, Okumura T, Miura K, Makishima H, et al. Proton Beam Therapy for Treating Patients with Hepatocellular Carcinoma with Major Portal Vein Tumor Invasion: A Single Center Retrospective Study. Cancers. 2024;16:2050.","journal-title":"Cancers"},{"key":"13739_CR22","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.radonc.2020.11.033","volume":"156","author":"P Munoz-Schuffenegger","year":"2021","unstructured":"Munoz-Schuffenegger P, Barry A, Atenafu EG, Kim J, Brierley J, Ringash J, et al. Stereotactic body radiation therapy for hepatocellular carcinoma with Macrovascular invasion. Radiother Oncol. 2021;156:120\u20136.","journal-title":"Radiother Oncol"},{"key":"13739_CR23","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.ijrobp.2017.12.288","volume":"110","author":"N Ohri","year":"2021","unstructured":"Ohri N, Tom\u00e9 WA, M\u00e9ndez Romero A, Miften M, Ten Haken RK, Dawson LA, et al. Local Control After Stereotactic Body Radiation Therapy for Liver Tumors. Int J Radiat Oncol Biol Phys. 2021;110:188\u201395.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"13739_CR24","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ijrobp.2023.08.015","volume":"118","author":"SH Bae","year":"2024","unstructured":"Bae SH, Chun S-J, Chung J-H, Kim E, Kang J-K, Jang WI, et al. Stereotactic body radiation therapy for hepatocellular carcinoma: meta-analysis and international stereotactic radiosurgery society practice Guidelines. Int J Radiat Oncol Biol Phys. 2024;118:337\u201351.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"13739_CR25","doi-asserted-by":"crossref","unstructured":"Korean Liver Cancer Association (KLCA) and National Cancer Center (NCC) Korea. 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma. Clin Mol Hepatol. 2022;28:583\u2013705.","DOI":"10.3350\/cmh.2022.0294"},{"key":"13739_CR26","doi-asserted-by":"crossref","unstructured":"The general rules for the clinical and pathological study of primary liver cancer. Liver Cancer Study Group of Japan. Jpn J Surg. 1989;19:98\u2013129.","DOI":"10.1007\/BF02471576"},{"key":"13739_CR27","doi-asserted-by":"crossref","unstructured":"Ueno S, Tanabe G, Nuruki K, Hamanoue M, Komorizono Y, Oketani M, et al. Prognostic performance of the new classification of primary liver cancer of Japan (4th edition) for patients with hepatocellular carcinoma: a validation analysis. Hepatol Res. 2002;24:395\u2013403.","DOI":"10.1016\/S1386-6346(02)00144-4"},{"key":"13739_CR28","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1159\/000439101","volume":"33","author":"M Kudo","year":"2015","unstructured":"Kudo M, Kitano M, Sakurai T, Nishida N. General rules for the clinical and pathological study of primary liver cancer, nationwide follow-up survey and clinical practice guidelines: the outstanding achievements of the liver cancer study group of Japan. Dig Dis. 2015;33:765\u201370.","journal-title":"Dig Dis"},{"key":"13739_CR29","doi-asserted-by":"publisher","first-page":"e0257556","DOI":"10.1371\/journal.pone.0257556","volume":"16","author":"C Khorprasert","year":"2021","unstructured":"Khorprasert C, Thonglert K, Alisanant P, Amornwichet N. Advanced radiotherapy technique in hepatocellular carcinoma with portal vein thrombosis: Feasibility and clinical outcomes. PLoS ONE. 2021;16:e0257556.","journal-title":"PLoS ONE"},{"key":"13739_CR30","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1748-717X-8-15","volume":"8","author":"J-Y Kim","year":"2013","unstructured":"Kim J-Y, Yoo E-J, Jang J-W, Kwon J-H, Kim K-J, Kay C-S. Hypofractionated radiotheapy using helical tomotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. Radiat Oncol. 2013;8:15.","journal-title":"Radiat Oncol"},{"key":"13739_CR31","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s00066-014-0643-z","volume":"190","author":"TH Kim","year":"2014","unstructured":"Kim TH, Park J-W, Kim Y-J, Kim BH, Woo SM, Moon SH, et al. Simultaneous integrated boost-intensity modulated radiation therapy for inoperable hepatocellular carcinoma. Strahlenther Onkol. 2014;190:882\u201390.","journal-title":"Strahlenther Onkol"},{"key":"13739_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","volume":"112","author":"R Timmerman","year":"2022","unstructured":"Timmerman R. A Story of Hypofractionation and the Table on the Wall. Int J Radiat Oncol Biol Phys. 2022;112:4\u201321.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"13739_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1159\/000531377","volume":"13","author":"M Kudo","year":"2024","unstructured":"Kudo M, Ueshima K, Saeki I, Ishikawa T, Inaba Y, Morimoto N, et al. A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial. Liver Cancer. 2024;13:99\u2013112.","journal-title":"Liver Cancer"},{"key":"13739_CR34","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"13739_CR35","doi-asserted-by":"crossref","unstructured":"Luo F, Li M, Ding J, Zheng S. The Progress in the Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. Frontiers in Oncology. 2021;11.","DOI":"10.3389\/fonc.2021.635731"},{"key":"13739_CR36","first-page":"39","volume":"4","author":"EB Holliday","year":"2017","unstructured":"Holliday EB, Tao R, Brownlee Z, Das P, Krishnan S, Taniguchi C, et al. Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus. Clin Transl Radiat Oncol. 2017;4:39\u201345.","journal-title":"Clin Transl Radiat Oncol"},{"key":"13739_CR37","doi-asserted-by":"publisher","first-page":"130","DOI":"10.17998\/jlc.18.2.130","volume":"18","author":"SH Bae","year":"2018","unstructured":"Bae SH, Kim M-S, Jang WI, Kim JH, Kim WC, Kim JH, et al. Multicenter Planning Comparison of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis (KROG 16\u201317). JLC. 2018;18:130\u201341.","journal-title":"JLC"},{"key":"13739_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.7314\/APJCP.2013.14.1.217","volume":"14","author":"S-L Li","year":"2013","unstructured":"Li S-L, Su M, Peng T, Xiao K-Y, Shang L-M, Xu B-H, et al. Clinicopathologic characteristics and prognoses for multicentric occurrence and intrahepatic metastasis in synchronous multinodular hepatocellular carcinoma patients. Asian Pac J Cancer Prev. 2013;14:217\u201323.","journal-title":"Asian Pac J Cancer Prev"},{"key":"13739_CR39","doi-asserted-by":"crossref","unstructured":"Kim N, Cheng J, Huang W-Y, Kimura T, Zeng ZC, Lee VHF, et al. Dose-Response Relationship in Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: A Pooled Analysis of an Asian Liver Radiation Therapy Group Study. International Journal of Radiation Oncology*Biology*Physics. 2021;109:464\u201373.","DOI":"10.1016\/j.ijrobp.2020.09.038"},{"key":"13739_CR40","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.3390\/cancers14184383","volume":"14","author":"T Kimura","year":"2022","unstructured":"Kimura T, Fujiwara T, Kameoka T, Adachi Y, Kariya S. The Current Role of Stereotactic Body Radiation Therapy (SBRT) in Hepatocellular Carcinoma (HCC). Cancers (Basel). 2022;14:4383.","journal-title":"Cancers (Basel)"},{"key":"13739_CR41","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1002\/cncr.21043","volume":"103","author":"DY Kim","year":"2005","unstructured":"Kim DY, Park W, Lim DH, Lee JH, Yoo BC, Paik SW, et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer. 2005;103:2419\u201326.","journal-title":"Cancer"},{"key":"13739_CR42","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/j.ijrobp.2011.04.011","volume":"81","author":"DL Andolino","year":"2011","unstructured":"Andolino DL, Johnson CS, Maluccio M, Kwo P, Tector AJ, Zook J, et al. Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011;81:e447-453.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"13739_CR43","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ijrobp.2017.01.221","volume":"97","author":"M Velec","year":"2017","unstructured":"Velec M, Haddad CR, Craig T, Wang L, Lindsay P, Brierley J, et al. Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2017;97:939\u201346.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"13739_CR44","doi-asserted-by":"publisher","first-page":"348","DOI":"10.4143\/crt.2013.142","volume":"46","author":"JI Yu","year":"2014","unstructured":"Yu JI, Yoon SM, Park HC, Kim JH, Kim TH, Park J-W, et al. Multicenter validation study of a prognostic index for portal vein tumor thrombosis in hepatocellular carcinoma. Cancer Res Treat. 2014;46:348\u201357.","journal-title":"Cancer Res Treat"},{"key":"13739_CR45","doi-asserted-by":"publisher","first-page":"177","DOI":"10.17998\/jlc.2023.03.04","volume":"23","author":"S Jin","year":"2023","unstructured":"Jin S, Choi W-M, Shim JH, Lee D, Kim KM, Lim Y-S, et al. Subclassification of advanced-stage hepatocellular carcinoma with macrovascular invasion: combined transarterial chemoembolization and radiotherapy as an alternative first-line treatment. J Liver Cancer. 2023;23:177\u201388.","journal-title":"J Liver Cancer"},{"key":"13739_CR46","doi-asserted-by":"publisher","first-page":"93","DOI":"10.21037\/tcr-22-1912","volume":"12","author":"S Zeng","year":"2023","unstructured":"Zeng S, Wang Z, Zhu Q, Li X, Ren H, Qian B, et al. Identification of risk and prognostic factors for intrahepatic vascular invasion in patients with hepatocellular carcinoma: a population-based study. Transl Cancer Res. 2023;12:93\u2013112.","journal-title":"Transl Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13739-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-13739-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-13739-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:17:58Z","timestamp":1745194678000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-13739-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["13739"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-13739-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"21 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of Seoul National University Hospital and Chung-Ang University Hospital. Informed consent requirement was waived by institutional review board of Seoul National University Hospital and Chung-Ang University Hospital due to the retrospective nature of the study. (IRB No. H-2205\u2013143-1327).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"736"}}